 |
|
The Incidence of AIDS-Defining Illnesses in 4883 Patients With Human Immunodeficiency Virus Infection
Amanda Mocroft, PhD;
Michael Youle, MBChD;
Andrew N. Phillips, PhD;
Ramesh Halai;
Phillipa Easterbrook, MD;
Margaret A. Johnson, MD;
Brian Gazzard, MD;
for the Royal Free/Chelsea and Westminster Hospitals Collaborative Group
Arch Intern Med. 1998;158:491-497.
Background Acquired immunodeficiency syndrome (AIDS)–defining illnesses are known to occur at different levels of immunosuppression, and the incidence of diagnoses may also vary according to the CD4 lymphocyte count strata. Information about the incidence of disease at different levels of immunosuppression would help clinicians monitoring patients and would allow prophylaxis to be targeted at the most appropriate population.
Methods Between 1982 and July 1995, 4883 patients testing positive for the human immunodeficiency virus were seen at either the Royal Free or Chelsea and Westminster Hospitals in London, England. The incidence of each diagnosis, both overall and stratified by CD4 lymphocyte count, was calculated using a person-years analysis. Patients who had no CD4 lymphocyte counts measured during follow-up were excluded from the analysis.
Results During a median follow-up period of 27.6 months, 3875 AIDS-defining illnesses were reported in 1713 patients. The incidence of AIDS-defining illnesses ranged from 6.22 per 100 person-years of follow-up for Pneumocystis carinii pneumonia (95% confidence interval, 5.74-6.70) to 0.37 for extrapulmonary tuberculosis (95% confidence interval, 0.26-0.48). The incidence of each AIDS-defining illness increased as the CD4 lymphocyte count declined; diagnoses such as cytomegalovirus and Mycobacterium avium–intracellulare complex infection had a low incidence at CD4 lymphocyte counts above 0.05x109/L (50/mm3), while Kaposi sarcoma, P carinii pneumonia, and esophageal candidiasis had a high incidence throughout all CD4 lymphocyte count strata.
Conclusions This study provides important information about the risk of AIDS-defining illnesses at lower CD4 lymphocyte counts, enabling disease-specific prophylaxis to be targeted at the most appropriate population. In the future, as more prophylactic therapies are developed, this study will provide historical data of the incidence of diseases before specific prophylaxis was introduced.
From the HIV Research Unit, Department of Primary Care and Population Sciences and Thoracic Medicine, Royal Free Hospital School of Medicine (Drs Mocroft, Phillips, and Johnson), the HIV/Genitourinary Medicine Research Unit, St Stephens Clinic (Drs Youle, Halai, and Gazzard), and the HIV Epidemiology Unit, Chelsea and Westminster Healthcare National Health Service Trust (Dr Easterbrook), London, England.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Gastrointestinal complications of HIV infection: changing priorities in the HAART era
Wilcox and Saag
Gut 2008;57:861-870.
ABSTRACT
| FULL TEXT
Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma
Lane et al.
J. Virol. 2002;76:11570-11583.
ABSTRACT
| FULL TEXT
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy
Kirk et al.
Blood 2001;98:3406-3412.
ABSTRACT
| FULL TEXT
Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected Patients after the Introduction of Highly Active Antiretroviral Therapy
KIRK et al.
Am. J. Respir. Crit. Care Med. 2000;162:865-872.
ABSTRACT
| FULL TEXT
Induction of HHV-8 Lytic Cycle Replication by Inflammatory Cytokines Produced by HIV-1-Infected T Cells
Mercader et al.
Am. J. Pathol. 2000;156:1961-1971.
ABSTRACT
| FULL TEXT
Discontinuation of Prophylaxis against Mycobacterium avium Complex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral Therapy
El-Sadr et al.
NEJM 2000;342:1085-1092.
ABSTRACT
| FULL TEXT
|
